C - Chemistry – Metallurgy – 07 – K
Patent
C - Chemistry, Metallurgy
07
K
C07K 16/46 (2006.01) A61K 47/48 (2006.01) A61P 1/00 (2006.01) A61P 3/10 (2006.01) C07K 16/44 (2006.01)
Patent
CA 2589800
Drug fusions and conjugates that contain an incretin therapeutic or diagnostic agent that is fused or conjugated to an antigen-binding fragment of an antibody that binds serum albumin. The conjugates and fusion have a longer in vivo half life in comparison with the unconjugated or unfused therapeutic or diagnostic agent.
La présente invention a trait à des fusions et conjugués médicamenteux contenant un agent thérapeutique et diagnostique à base d'incrétine qui est fusionné ou conjugué à un fragment de liaison à l'antigène d'un anticorps de liaison à l'albumine sérique. Les conjugués et fusions ont une durée de vie plus longue in vivo comparés à l'agent thérapeutique ou diagnostique non conjugué ou non fusionné.
Holmes Steve
Holt Lucy J.
Jespers Laurent S.
Tomlinson Ian M.
Domantis Limited
Norton Rose Or S.e.n.c.r.l. S.r.l./llp
LandOfFree
Bispecific domain antibodies targeting serum albumin and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bispecific domain antibodies targeting serum albumin and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bispecific domain antibodies targeting serum albumin and... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1368209